---
layout: topic-review
title: "Hepatobiliary"
redirect_from:
  - /absite/09_07-hepatobiliary/
permalink: /landmark/topic-review/hepatobiliary/
---

# Hepatobiliary Review

Use the collapsible sections below. The floating Table of Contents on the right lists all major headings (≤20) for quick navigation.

---

<details open>
<summary><strong>Liver</strong></summary>

<br>

### Anatomy & Variants
- **Lobar/segmental anatomy:** Cantlie’s line (GB fossa → IVC) divides right/left lobes. Couinaud segments I–VIII; **I = caudate** (separate inflow from both sides; drains directly to IVC).
- **Portal triad (hepatoduodenal ligament):** common bile duct (lateral), portal vein (posterior), proper hepatic artery (medial).  
  *Pearl:* Pringle maneuver (porta clamp) **does not** stop hepatic vein bleeding.
- **Hepatic artery variants (common):**  
  - Replaced **right** hepatic off SMA (behind pancreas, posterolateral to CBD).  
  - Replaced **left** hepatic off left gastric (within gastrohepatic ligament).
- **Venous drainage:** 3 hepatic veins → IVC; middle often joins left before IVC. Accessory right hepatic veins common.
- **Relationships/landmarks:** Foramen of Winslow—ant: portal triad; post: IVC; inf: duodenum; sup: caudate.

### Physiology, Bilirubin & Bile
- **Storage/production:** Urea synthesized in liver; stores fat-soluble vitamins + B12. Not synthesized in liver: vWF, factor VIII (endothelium).
- **Metabolic sensitivity:** Zone III (centrilobular) hepatocytes most ischemia-sensitive.
- **Resection tolerance:** Up to ~75% normal liver safely resectable with adequate function (see FLR below).
- **Bilirubin pathway:** Heme → biliverdin → **unconjugated bilirubin** → hepatic conjugation (glucuronyl transferase) → biliary excretion → gut bacteria → urobilinogen → urine **urobilin** (dark “cola” urine when excess).  
  - **Unconjugated ↑:** hemolysis, impaired uptake/conjugation (e.g., Gilbert, Crigler–Najjar).  
  - **Conjugated ↑:** secretion/excretion defects (hepatitis, obstruction).  
  - Hepatitis labs: very high AST/ALT, modest Alk Phos. Obstruction: very high Alk Phos, modest transaminases.
- **Bile composition:** bile salts (~85%), phospholipids (lecithin), cholesterol, bilirubin, proteins. GB concentrates bile via water reabsorption; lecithin emulsifies fat; primary bile acids (cholic/chenodeoxycholic) → secondary (deoxy-/lithocholic).

### Viral Hepatitis
- **Acute hepatitis:** avoid surgery in acute phase; fulminant failure possible (B, D, E; rare with A, C).  
- **Chronic risk:** B, C, D → chronic hepatitis ± HCC.  
- **Key facts:**  
  - **HBV:** anti-HBc IgM (first 6 mo), vaccine → anti-HBs only; recovery: anti-HBc + anti-HBs, no HBsAg.  
  - **HCV:** leading viral indication for transplant (modern DAAs ~95% cure).  
  - **HEV in pregnancy:** fulminant failure risk (3rd trimester).  
  - **HBV + HDV:** highest mortality.  
  *Pearl:* No biopsy needed for classic HCC imaging with elevated AFP.

### Liver Failure, Ascites & Encephalopathy
- **Cirrhosis:** most common cause of failure; best synthetic function marker: **PT/INR**.  
- **Acute (fulminant) failure:** ~80% mortality; prognosis by encephalopathy course; consider urgent TXP if **King’s College** criteria met.  
- **Hepatic encephalopathy:** ammonia, false neurotransmitters; triggers—GI bleed, infection (SBP), electrolytes, meds.  
  - **Tx:** lactulose (titrate 2–3 stools/day), protein restriction (≤70 g/d initially), consider branched-chain AAs; antibiotics only for infection.  
- **Ascites:** splanchnic/portal lymph leak with portal HTN.  
  - **Tx:** Na restriction, fluid restriction, **spironolactone** (hyperaldosteronism), paracentesis (replace albumin ≈1 g/100 mL removed), TIPS if refractory; SBP prophylaxis (e.g., norfloxacin) after SBP or variceal UGI bleed.  
- **Hepatorenal syndrome:** prerenal-like labs unresponsive to volume; stop diuretics, give albumin, vasoconstrictors; definitive = transplant.  
- **SBP:** ascites + fever/abd pain; PMN >250; mono-organism (E. coli #1). **Tx:** 3rd-gen cephalosporin; expect response ≤48 h.  
  *Pearl:* Postpartum liver failure + ascites → consider hepatic vein thrombosis (pelvic septic thrombophlebitis).

### Portal Hypertension & Varices
- **Sites of resistance:** presinusoidal (schisto, PVT), sinusoidal (cirrhosis), postsinusoidal (Budd–Chiari, constrictive pericarditis/CHF).  
- **Significant pressure:** portal (wedged hepatic venous) pressure >10 mmHg; variceal rupture ≈ HVPG ≥12 mmHg.  
- **Collaterals:** gastroesophageal, rectal, umbilical (caput medusae).  
- **Variceal bleed management:** resuscitate (type/cross, antibiotics), airway protection; **octreotide** → endoscopic banding; **TIPS** if uncontrolled or rebleed after 2nd endoscopy.  
  - **Propranolol** for secondary prophylaxis; vasopressin + NTG if needed (CAD caution).  
- **Shunts:**  
  - **TIPS** (rapid decompression; encephalopathy risk).  
  - **Selective distal splenorenal (Warren):** Child A with bleeding only (doesn’t help ascites).  
  - **Partial portosystemic (calibrated PV–IVC graft):** if TIPS unavailable, refractory ascites.  
- **Umbilical hernia with ascites:** electively repair after ascites control and coagulopathy correction; **mesh** if elective (no drains); urgent repair without mesh for incarceration/rupture/infection; aggressive postop ascites control.  
  *Pearl:* Ascites control is the single best way to reduce hernia complications and recurrence.

<div class="qr-table">
<caption>Portal Hypertension – Treatment Map</caption>

| Scenario / indication | First-line therapy | Procedure / shunt | Notes |
|---|---|---|---|
| **Acute variceal bleed** | Resuscitate + antibiotics → **octreotide** → **endoscopic banding** | **TIPS** if uncontrolled or early rebleed | Intubate if airway risk; vasopressin + NTG as bridge |
| **Secondary prophylaxis** | **Non-selective β-blocker** ± repeat banding | — | Reduces rebleed and mortality |
| **Refractory ascites** | Max diuretics, paracentesis + albumin | **TIPS** (if reasonable liver function) | Watch encephalopathy risk |
| **Child A, isolated bleeding** | BB + banding | **Distal splenorenal (Warren)** (selective) | Doesn’t help ascites |
| **Shunt needed, ascites predominant, TIPS not available** | Medical optimization | **Partial PV–IVC interposition** (calibrated) | “Partial”/calibrated side-to-side |
| **Extensive portal thrombosis; no shunt options** | Medical/endoscopic | **Devascularization** (rare) | Historical; TIPS has displaced many cases |
</div>

### Hepatic Vascular Disorders
- **Budd–Chiari (hepatic vein/IVC occlusion):** RUQ pain, hepatosplenomegaly, ascites, failure; RF: polycythemia vera. Dx: venous-phase imaging/biopsy (sinusoidal congestion). Tx: portacaval shunt (above obstruction), consider catheter-directed tPA if acute.  
- **Splenic vein thrombosis:** **isolated gastric varices** (portal pressure elsewhere normal); cause: pancreatitis; **Tx: splenectomy** if bleeding.  
- **Portal vein thrombosis:** extrahepatic; hypercoagulable states; ascites without liver failure; varices common (children: MCC massive hematemesis). Tx: heparin if acute (avoid during active UGI bleed); eventual shunt if needed.

### Liver Abscesses
- **Pyogenic** (>80%): right lobe; biliary source (cholangitis) common; **E. coli** #1. Dx: aspiration. **Tx:** CT-guided drain + antibiotics (op if unstable/failure).  
- **Amebic:** single right-lobe lesion; RF travel (Mexico), ETOH; serology positive; **Tx:** metronidazole (drain only if refractory/rupture).  
- **Echinococcus (hydatid):** double-walled cyst (ecto/endocyst); **don’t aspirate** (anaphylaxis); preop albendazole → careful excision; inject scolicidal agent intraop; avoid spillage.  
- **Schistosomiasis:** eosinophilia, water exposure; can cause variceal bleeding; **Tx:** praziquantel + variceal management.

### Tumors (Benign & Malignant)
- **Hemangioma:** most common benign; peripheral-to-central fill on CT/MRI; very bright T2; avoid biopsy. **Tx:** observe regardless of size unless symptomatic → resect ± embolization. Rare: Kasabach–Merritt (consumptive coagulopathy).  
- **FNH:** women; central stellate scar; has Kupffer cells (sulfur colloid uptake). **Tx:** observation (no malignancy/bleed risk).  
- **Adenoma:** OCPs/anabolic steroids; right lobe; 10% malignant; **bleeding risk ↑ with size** (>4–5 cm). **Tx:** stop OCPs (regress?) → resect if >4 cm, symptomatic, no regression; rupture → emergent embolization → delayed resection.  
  *Pearl:* Sulfur colloid uptake: **positive = FNH**, **negative = adenoma**.  
- **HCC:** risks—HBV/HCV, alcohol cirrhosis, hemochromatosis, A1AT, aflatoxin, PSC; lung = most common metastasis.  
  - **Diagnosis:** arterial hyperenhancement with portal/delayed washout + ↑AFP → no biopsy needed.  
  - **Resection candidacy:** solitary without major vascular invasion and adequate function. **FLR**: no cirrhosis ≥25%; Child A ~30–40%; consider **portal vein embolization** if marginal FLR. Margin goal ~1 cm.  
  - **Transplant:** early stage with moderate–severe cirrhosis; **Milan criteria:** single <5 cm **or** ≤3 all <3 cm, no gross vascular/extrahepatic spread.  
  - **Locoregional:** <5 cm ablation; >5 cm **TACE**; consider external beam RT if not ablation/TACE candidate.  
  - **Fibrolamellar HCC:** young, noncirrhotic; **neurotensin** marker; better prognosis (high recurrence).
- **Metastases:** more common than primary (≈20:1). **CRC mets** resection if adequate FLR → ~35% 5-yr survival.

<div class="qr-table">
<caption>HCC – Resection vs Transplant vs Bridge</caption>

| Liver function / tumor status | Resection | Transplant | Bridge / Other |
|---|---|---|---|
| **No cirrhosis, solitary, no major vascular invasion** | **Yes** if adequate FLR (≥25%) | No | Consider ablation if ≤5 cm but resection preferred |
| **Child A, early stage (no portal HTN)** | **Possible** (FLR ~30–40%) | Consider if not resectable | PVE if marginal FLR; ablation if ≤5 cm |
| **Child B–C, early stage meeting Milan** | Often **No** | **Yes** (Milan: 1 × <5 cm or ≤3 × <3 cm, no macrovascular/extrahepatic disease) | **TACE/ablation** as bridge to TXP |
| **Multifocal beyond Milan** | Rarely | No (unless downstaged) | Downstage with **TACE/ablation**; consider trial/downstaging protocols |
| **Major vascular invasion / extrahepatic spread** | No (controversial exceptions) | No | Systemic/RT/clinical trial; palliation |
</div>

<details>
<summary><strong>Liver Q&amp;A Review (condensed)</strong></summary>

- What divides right/left lobes? **Cantlie’s line** (GB fossa → IVC).  
- Common hepatic artery variants? **Replaced RHA from SMA** (behind pancreas/CBD), **replaced LHA from left gastric** (gastrohepatic ligament).  
- Variceal rupture HVPG? **≈12 mmHg** (portal HTN >6–10 mmHg).  
- Best function marker in cirrhosis? **PT/INR**.  
- SBP diagnosis? **PMN >250**; tx **3rd-gen cephalosporin**.  
- Budd–Chiari risk? **Polycythemia vera**; tx **shunt above obstruction** ± catheter tPA (acute).  
- HCC FLR thresholds? **No cirrhosis ≥25%; Child A ~30–40%**.  
- Milan criteria? **1 <5 cm or ≤3 all <3 cm; no vascular/extrahepatic disease**.  
- FNH vs adenoma sulfur colloid? **FNH + / adenoma –**.  
- Umbilical hernia in ascites? Elective after control; **mesh** if clean; **no mesh** if contaminated/urgent.

</details>

</details>

---

<details>
<summary><strong>Biliary</strong></summary>

<br>

### Anatomy & Physiology
- **GB position:** under segments IV–V. **Cystic artery** from right hepatic within Calot’s triangle (cystic duct lateral, CHD medial).  
- **Duct blood supply:** longitudinal at 3 & 9 o’clock (retroduodenal GDA medially; right hepatic laterally).  
- **Normal diameters:** CBD ≤6 mm (≤10 mm post-chole); GB wall ≤4 mm; pancreatic duct ≤4 mm.  
- **Sphincter of Oddi:** **morphine contracts**, **glucagon relaxes**.  
- **Ducts of Luschka** can leak postop; Rokitansky–Aschoff sinuses with chronically ↑ intraluminal pressure.

### Gallstones & Cholecystitis (incl acalculous/emphysematous)
- **Stones:** ~10% prevalence; most asymptomatic → observe.  
  - **Cholesterol** (most US): GB stasis, nucleation; largely in GB.  
  - **Black pigment:** hemolysis/cirrhosis/TPN.  
  - **Brown pigment (primary CBD):** infection (β-glucuronidase) → evaluate ampulla/diverticula; many need sphincteroplasty.  
- **Biliary colic:** transient cystic-duct obstruction; resolves 4–6 h → elective chole if stones on US.  
- **Acute calculous cholecystitis:** RUQ pain ± Murphy; US: stones, wall thickening >4 mm, pericholecystic fluid; HIDA most sensitive. **Tx:** early lap chole if fit; no benefit to “cool-off.”  
  - **Too ill:** cholecystostomy → interval chole.  
  - **Pregnancy:** lap chole (prefer 2nd trimester), open Hasson entry, low insufflation, left tilt.  
  - **Cirrhosis:** chole once compensated (experienced surgeon; correct coagulopathy).  
- **Acalculous cholecystitis:** burns/TPN/trauma/ICU; stasis/ischemia; **Tx:** chole or percutaneous drain if unstable.  
- **Emphysematous cholecystitis:** diabetics; *Clostridium perfringens*; urgent source control.

### Choledocholithiasis, Cholangitis & Obstruction (ERCP/MRCP/IOC)
- **Strong suspicion of CBD stone** (stone on imaging, cholangitis, bili >3, dilated CBD): **pre-op ERCP** for clearance (IOC/lap CBD exploration if ERCP unavailable).  
- **Moderate suspicion** (abnormal LFTs, mild bili ↑, gallstone pancreatitis without cholangitis): **MRCP or IOC** (ERCP if confirmed obstruction).  
- **Low suspicion:** proceed to chole without further testing.  
- **Intra-op stone on IOC:** flush + glucagon (×2 max); transcystic exploration if feasible; otherwise lap CBD exploration or post-op ERCP per resources.  
- **Cholangitis:** Charcot triad (fever, jaundice, RUQ pain) ± Reynolds pentad (shock, AMS). **Tx:** fluids + antibiotics → **emergent ERCP** with sphincterotomy/extraction; **PTC** if ERCP fails; chole before discharge.  
  *Pearl:* **GGT** has very high NPV for choledocholithiasis when normal.
- **RYGB anatomy:** if GB present → chole + intra-op CBD exploration; if GB absent → double-balloon ERCP or lap G-tube into remnant for ERCP.

<div class="qr-table">
<caption>Choledocholithiasis – Workup Summary</caption>

| Clinical likelihood | Typical findings | First test | Next step if positive | Definitive management |
|---|---|---|---|---|
| **Strong** | CBD stone on imaging, cholangitis, Tbili >3, CBD ≥6–7 mm | **ERCP** (diagnostic + therapeutic) | Sphincterotomy ± extraction/stent | Cholecystectomy same/next admission once sepsis controlled |
| **Moderate** | Abnl LFTs (not just bili), mild bili ↑, GSP without cholangitis | **MRCP** *or* **IOC** | If stone confirmed → ERCP or lap CBD exploration | Proceed to chole after duct clearance |
| **Low** | No labs/imaging suggesting CBD stone | **No pre-op imaging** | Intra-op IOC per surgeon preference | Standard chole; manage stones if found |
| **Post-chole retained stone** | Jaundice/colic after chole | **US ± MRCP** | **ERCP** (~95% clearance) | Stent if needed; treat stricture if present |
| **RYGB anatomy** | Altered access | — | Double-balloon ERCP **or** lap transgastric ERCP **or** intra-op exploration | Tailor to local expertise/resources |
</div>

### Bile Duct Injury & Stricture
- **Etiology:** most after lap chole; excess cephalad fundus retraction and misidentification.  
- **Intra-op troubleshooting:** if hepatic ducts don’t fill on IOC → withdraw catheter, flush, Trendelenburg; **convert to open** if concern for injury.  
- **Partial (<50%) CBD injury:** primary repair possible; otherwise **hepaticojejunostomy (HJ)** (avoid trying to reach duodenum).  
- **Post-op bile leak:** image/drain collection; if bilious → **ERCP + sphincterotomy/stent** for cystic stump/small injuries/Luschka.  
- **Complete transection:** **PTC** to decompress → **HJ** (≤7 d: immediate if feasible; >7 d: delay 6–8 wk for tissue to mature).  
- **Benign late stricture:** ischemia after chole most common; **MRCP** for roadmap; oncologic workup if needed; durable repair = **choledochojejunostomy**.

### Benign GB (Polyps, Adenomyomatosis, Cholesterolosis)
- **Polyps management:**  
  - **6–9 mm:** yearly US; operate if high-risk features (stones, sessile, rapid growth, infundibular polyp, wall abnormality, age >50).  
  - **≥10–18 mm:** lap chole.  
  - **>18 mm:** treat as GB cancer.  
- **Adenomyomatosis (RA sinuses):** non-premalignant; chole if symptomatic.  
- **Cholesterolosis:** speckled mucosa; ceftriaxone can precipitate sludge/cholestatic jaundice.  
- **Prophylactic chole** may be reasonable in transplant or RYGB candidates with stones.

<div class="qr-table">
<caption>Gallbladder Polyp – Management Algorithm</caption>

| Polyp size | High-risk features present?* | Action | Rationale |
|---|---|---|---|
| **≤5 mm** | No | Observe; no routine follow-up | Very low malignancy risk |
| **6–9 mm** | No | Annual US surveillance | Low risk; monitor growth |
| **6–9 mm** | **Yes** | **Cholecystectomy** | Stones, sessile, rapid growth, infundibular polyp, wall changes, age > 50 |
| **≥10–18 mm** | — | **Cholecystectomy** | Size threshold for malignancy risk |
| **>18 mm** | — | Treat as **GB cancer** until proven otherwise | High malignant potential |

*High-risk features: gallstones, symptoms, sessile morphology, rapid growth, infundibular location, wall abnormality, age >50.
</div>

### Malignancy & Choledochal Cysts
- **Gallbladder adenocarcinoma:** RFs—stones (#1), polyps ≥10 mm, porcelain GB (risk lower than once thought), typhoid, PSC/IBD; liver most common metastasis.  
  - **Incidental T1a (lamina propria):** chole alone.  
  - **≥T1b (muscularis):** chole + wedge of IVb/V + portal LND; extend as needed for margins. **No port-site excision**.  
- **Cholangiocarcinoma:** intrahepatic or extrahepatic; RFs—PSC, choledochal cysts, stones, liver flukes, HBV/HCV.  
  - **Dx:** MRCP/contrast MRI ± laparoscopy; resect if no distant or prohibitive nodal disease (extrahepatic: avoid SMA/celiac nodes).  
  - **Hilar (Klatskin):** often unresectable; distal → Whipple. **Transplant not for multifocal cholangio.**  
- **Choledochal cysts (Todani):** majority extrahepatic; **malignant potential ~15%**.  
  - **I (fusiform CHD/CBD):** excision + hepaticojejunostomy.  
  - **II (CBD diverticulum):** excision ± Roux reconstruction.  
  - **III (choledochocele):** transduodenal excision or sphincteroplasty.  
  - **IVa (intra+extrahepatic):** hepatic resection + biliary reconstruction. **IVb (extra only):** excision + HJ.  
  - **V (Caroli):** transplant (consider partial resection if localized).

### Cholestatic Diseases (PSC / PBC)
- **PSC:** men; IBD association (UC); multifocal intra/extrahepatic strictures; pruritus/jaundice; complications—cirrhosis, cholangiocarcinoma. **Tx:** symptom control (cholestyramine/UDCA), dilations/stents as needed; **transplant** for failure.  
- **PBC:** women; antimitochondrial Ab+; cholestasis → portal HTN; **Tx:** UDCA ± cholestyramine; **transplant** for liver failure.

### Special Situations & Hemobilia
- **Gallstone ileus:** cholecystoenteric fistula → SBO (IC valve common). **Tx:** enterotomy proximal to obstruction, milk stone back, remove; **avoid** simultaneous chole + fistula takedown (higher morbidity; low recurrence).  
- **Post-lap chole “shock”:** early = hemorrhage (cystic-artery clip); **late = septic shock** from clipped CBD → cholangitis.  
- **Pneumobilia:** prior ERCP/sphincterotomy most common; also gallstone ileus or ongoing infection.  
- **Hemobilia:** hepatic artery–bile duct fistula (trauma, PTC). UGIB with blood from ampulla on EGD; **Tx: angioembolization**.

<details>
<summary><strong>Biliary Q&amp;A Review (condensed)</strong></summary>

- CBD diameter norms? **≤6 mm** (≤10 mm post-chole).  
- Sphincter pharmacology? **Morphine contracts; glucagon relaxes.**  
- Cholecystitis in pregnancy? **2nd-trimester lap chole; Hasson entry; low insufflation; left tilt.**  
- Strong CBD stone suspicion? **Pre-op ERCP** (or IOC/lap exploration if unavailable).  
- Cholangitis first-line decompression? **ERCP** (PTC if ERCP fails).  
- IOC doesn’t show ducts? **Withdraw/flush, Trendelenburg; convert to open if injury suspected.**  
- Post-chole bile leak? **Drain + ERCP/stent**.  
- Complete transection timing? **≤7 d immediate HJ if feasible; >7 d delay 6–8 wk**.  
- GB polyp thresholds? **6–9 mm US yearly; ≥10 mm chole; >18 mm treat as cancer** (operate for high-risk features regardless of size).  
- Isolated gastric varices cause? **Splenic vein thrombosis (pancreatitis) → splenectomy.**

</details>

</details>

---

## Figures

![Figure from page 66](./images/09_07-hepatobiliary_p66_i1.png)
![Figure from page 67](./images/09_07-hepatobiliary_p67_i1.png)
![Figure from page 68](./images/09_07-hepatobiliary_p68_i1.png)
![Figure from page 70](./images/09_07-hepatobiliary_p70_i1.png)
![Figure from page 73](./images/09_07-hepatobiliary_p73_i1.png)
![Figure from page 75](./images/09_07-hepatobiliary_p75_i1.png)
![Figure from page 77](./images/09_07-hepatobiliary_p77_i1.png)
![Figure from page 79](./images/09_07-hepatobiliary_p79_i1.png)
![Figure from page 80](./images/09_07-hepatobiliary_p80_i1.png)
![Figure from page 82](./images/09_07-hepatobiliary_p82_i1.png)
